Natera stock gains as Q3 revenue reaches 794 million US dollars
Published on 11/09/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth Meets Higher Guidance
- Natera reported third-quarter revenue growth of 34.1 percent, supported by higher testing volumes and average selling prices.
- Oncology testing increased 60.9 percent year over year, keeping cancer monitoring central to the expansion strategy.
- The company remains loss-making as spending on clinical development and commercial capacity rises.
Natera stock gained ground after the diagnostics company reported strong third-quarter growth and raised its full-year revenue outlook. The results covered the period ended September 30 and were reported after the US market closed on Thursday, November 5.
Revenue and testing volumes accelerate
Natera generated revenue of 794.0 million US dollars in the third quarter, up 34.1 percent from 592.2 million US dollars a year earlier. The company attributed the increase to higher testing volume and improved average selling prices. Gross margin was 64.7 percent, compared with 64.9 percent in the prior-year quarter.
Total testing increased to 1,093,100 from 893,600. Oncology testing grew to 339,500 from 211,000, a 60.9 percent increase that keeps cancer monitoring at the center of Natera's growth strategy.
Higher outlook, ongoing investment
Natera raised its 2026 revenue outlook to 3.005 billion to 3.035 billion US dollars from 2.850 billion to 2.910 billion US dollars. The midpoint increased by 140 million US dollars. Management kept its gross-margin outlook at approximately 64 percent to 66 percent and expects positive cash flow.
Operating expenses rose 19.5 percent to 576.1 million US dollars, reflecting higher headcount for new products and increased clinical-trial costs. The net loss narrowed to 59.9 million US dollars, or 0.42 US dollars per diluted share, from 87.5 million US dollars, or 0.64 US dollars per share, in the year-earlier quarter.
What changed since the latest report
Natera stock traded at 286.80 euros on Lang & Schwarz at 4:09 p.m. CET on Monday, November 9, 2026. That was 1.86 percent above the 281.55 euro quote in the latest relevant report published earlier the same day, a separate comparison from any daily exchange close.
For investors, the higher sales range improves the fundamental growth reference point, while continued losses and rising spending keep execution and operating leverage in focus. The next quarterly update will show whether testing growth and pricing improvements are carrying the revised outlook toward its upper end.
For broader US market context, see the S&P 500 market topic.
Natera, Inc. stock facts
- Company: Natera, Inc.
- ISIN: US6323071042
- Ticker: NTRA
- Lang & Schwarz quote: 286.80 euros at 16:09 CET on November 9, 2026
- Change since latest report: 1.86 percent above 281.55 euros at 14:34 CET on November 9, 2026
